Explainable Artificial Intelligence For The Detection and Characterisation of Stage B Heart Failure

Ahmed M Salih, Emer Brady, Ranjit Arnold, Gaurav Gulsin, Huiyu Zhou, Anvesha Singh, Gerry McCann · 2026

Read Explainable Artificial Intelligence For The Detection and Characterisation of Stage B Heart Failure by Ahmed M Salih, Emer Brady, Ranjit Arnold, Gaurav Gulsin, Huiyu Zhou, Anvesha Singh, Gerry McCann (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2606-30665.txt.

Introduction

Ahmed Salih and six colleagues review explainable AI for Stage B heart failure, the stage where the heart shows structural or functional faults but causes no symptoms yet. Catching people at this stage matters, because treatment can still prevent full symptomatic failure. Explainable AI promises detection tools whose reasoning clinicians can inspect, unlike black-box scores.

The review searched three major databases in March 2026 and kept twenty studies that applied AI with explanation methods to Stage B disease. SHAP, which assigns each input a contribution score, was the most used method, ahead of LIME, saliency maps and Grad-CAM. Adoption was uneven, though, and explanation quality was often never tested. No study compared explanations by sex or ethnic subgroup, despite known differences in disease burden. The authors conclude that explainability is not yet validated well enough for fair, general clinical use.

Catalog record

CREATORAhmed M Salih, Emer Brady, Ranjit Arnold, Gaurav Gulsin, Huiyu Zhou, Anvesha Singh, Gerry McCann
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2606.30665

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Explainable Artificial Intelligence For The Detection and Characterisation of Stage B Heart Failure Ahmed M Salih, Emer Brady, Ranjit Arnold, Gaurav Gulsin, Huiyu Zhou, Anvesha Singh, Gerry McCann Abstract Background: Stage B heart failure is characterised by asymptomatic structural or functional cardiac abnormalities. Identifying individuals at this stage of diseases is clinically important, as early detection may enable the use of targeted interventions to prevent progression to symptomatic heart failure. Explainable artificial intelligence (XAI) may facilitate early detection, transparent risk stratification, and appropriate selection of clinically actionable intervention to prevent disease progression. Objective: To review the use of XAI methods in detecting and characterising stage B heart failure. Methods: A literature search of Web of Science, Scopus, and PubMed was conducted on 27 March 2026. Studies were included if they applied AI with XAI techniques to stage B heart failure. After screening, 20 studies were included. Data on modalities, outcomes, demographic reporting, and XAI methods were extracted and synthesised. Results: SHAP was the most commonly used explainable AI method, followed by LIME, saliency maps, and Grad-CAM; however, XAI adoption remained inconsistent, with several studies relying on limited or ad hoc interpretability approaches. Importantly, none of the studies generated or compared explanations across sex or ethnic subgroups, despite evidence of subgroup-specific differences in disease burden. Furthermore, evaluation of XAI outputs was often lacking: some studies did not assess explanations at all, while others relied solely on literature-based comparisons, which may introduce bias and subjectivity. Together, these limitations indicate that explainability was not systematically validated or leveraged to support fair and generalisable clinical inference.. Conclusion: XAI shows promise for improving transparency in Stage B heart failure identification, but current implementations remain limited. Major gaps include insufficient consideration of sex and ethnicity, lack of subgroup-specific explainability analyses, inconsistent XAI evaluation, and limited external validation, all of which constrain generalisability and clinical adoption. Keywords— Explainable AI, Stage B Heart Failure, Early detection 1 Introduction Heart failure (HF) remains a major global health challenge, affecting more than 60 million people worldwide and contributing substantially to morbidity, mortality, and healthcare expenditure [ 6 ] . Although HF is typically diagnosed at symptomatic stages, mounting evidence demonstrates that the disease process begins much earlier, with subtle structural or functional cardiac abnormalities that precede overt clinical manifestations. This early stage is referred to as stage B heart failure (SBHF), which is asymptomatic and represents a critical window during which targeted interventions may prevent or delay progression to symptomatic HF [ 7 ] . Detecting individuals at this stage therefore is clinically relevant, yet conventional diagnostic approaches, including electrocardiography, echocardiography, and biomarker assessment, may lack sufficient sensitivity or interpretability to reliably identify these early abnormalities. Artificial intelligence (AI) has emerged as a powerful tool in cardiovascular medicine, offering enhanced pattern recognition and predictive capabilities beyond traditional statistical methods [ 20 ] . AI models have demonstrated promise in identifying SBHF from diverse data sources, including imaging, physiological signals, and laboratory biomarkers. However, the clinical translation of AI remains limited by the “black-box” nature of many algorithms, which obscures the reasoning behind model predictions and restricts clinician trust, regulatory acceptance, and integration into clinical decision-making. Explainable AI (XAI) seeks to address this challenge by providing transparent, interpretable insights into model behaviour. Techniques such as SHapley Additive exPlanations (SHAP), Local Interpretable Model-Agnostic Explanations (LIME), saliency maps, integrated gradients, and Gradient-weighted Class Activation Mapping (Grad-CAM) offer mechanisms to visualize feature importance, highlight influential imaging regions, and reveal underlying decision pathways [ 22 ] . In the context of SBHF, XAI has the potential not only to improve clinicians’ confidence in AI-derived predictions but also to accelerate discovery of novel disease mechanisms, risk markers, and prognostic indicators. This review therefore aims to synthesise current evidence on the use of XAI techniques in identifying SBHF. We summarize the AI and XAI methods employed across studies, highlight trends in data sources and clinical outcomes, and discuss key challenges and opportunities for advancing interpretable AI in the SBHF. 2 Stage B Heart Failure HF is defined by the 2022 American Heart Association (AHA)/American College of Cardiology (ACC) / Heart Failure Society of America (HFSA) guideline as a clinical syndrome resulting from structural and/or functional cardiac abnormalities that impair the heart’s ability to meet the metabolic demands of the body. Typical symptoms are breathlessness, fatigue with or without signs of fluid retention. The guideline emphasizes HF as a progressive condition, occurring across a continuum from risk factors to advanced symptomatic disease, where early recognition and prevention are crucial [ 12 ] . Figure 1 illustrates the stages of HF based on the 2022 AHA/ACC/HFSA guideline [ 12 ] defining four distinct phases in HF development. Stage A, termed “At risk for HF,” includes individuals without structural heart disease or symptoms but who possess risk factors known to predispose them to HF, such as hypertension, diabetes, obesity, or a family history of cardiomyopathy. Importantly, these individuals have no imaging or biomarker evidence of cardiac injury, and interventions focus on aggressive risk factor modification. Figure 1 : Heart failure stages. LVH: left ventricular hypertrophy; LVD: left ventricular dysfunction. SBHF, now defined as “Pre-heart failure,” includes people who remain asymptomatic but demonstrate structural heart disease or elevated filling pressures, or have persistent elevations in biomarkers indicative of myocardial stress or injury [ 4 ] . SBHF is primarily identified by cardiac imaging revealing structural or functional abnormalities such as left ventricular hypertrophy or reduced ejection fraction, and may be supported by elevated circulating biomarkers, particularly brain natriuretic peptide. These structural abnormalities reflect early cardiac remodelling and place individuals at increased risk for progression to symptomatic HF. Prevention strategies in SBHF emphasize guideline directed medical therapies to halt or slow disease progression. Across the literature, SBHF is described using heterogeneous terminology, including asymptomatic structural heart disease, left ventricular dysfunction [ 29 ] , subclinical left ventricular dysfunction, left ventricular hypertrophy [ 24 ] , left ventricular remodelling, and preclinical heart failure. These terms generally refer to the same clinical construct of structural or functional cardiac abnormalities in the absence of overt heart failure symptoms. For clarity and consistency, this manuscript adopts the AHA/ACC/HFSA classification and refers to this stage uniformly as SBHF. Previous studies showed that SBHF might progress over time to symptomatic heart failure with potential to regress to stage A. A subset of individuals with SBHF were observed to regress to stage A in a study conducted as part of the Olmsted County Heart Function Study [ 27 ] . This reversibility highlights SBHF as a critical window for the application of AI methods to identify high-risk individuals early and enable timely, targeted interventions before irreversible disease progression occurs. 3 Explainable AI XAI refers to a set of methods that help end-users (e.g., clinicians) understand why an AI model has made a particular prediction. While AI can analyze large volumes of clinical, imaging, and biomarker data far beyond what the human eye can detect, clinicians often hesitate to rely on these systems because many operate as "black boxes" producing outputs without showing their reasoning. XAI aims to bridge this gap by providing clear, interpretable information that supports clinical decision-making rather than replacing it [ 23 ] . XAI methods

Read the complete text